Cissus para Fracturas óseas y dolor óseo
Cissus quadrangularis — 9 estudios científicos revisados
Strong¿Sirve Cissus para fracturas óseas y dolor óseo?
La planta contiene fitoesteroles y otros compuestos que promueven la remodelación ósea y la curación de tejidos, ayudando a la regeneración tras una lesión.
Compuestos activos involucrados: Alcaloides, Flavonoides, Polifenoles, Saponinas, Terpenos, Glucósidos, Irido, Terpenoides
Evidencia Científica
Los siguientes estudios han investigado la relación entre Cissus y fracturas óseas y dolor óseo:
Cissus quadrangularis L: A comprehensive multidisciplinary review.
ETHNOPHARMACOLOGICAL RELEVANCE: Cissus quadrangularis L. is a perennial herb of the Vitaceae family and is utilized comprehensively as a medicinal herb in most tropical regions by various names. This herb is documented to possess a wide-ranging ethnomedicinal uses in malaria, fever, epilepsy, gout, piles, skin diseases, colic, etc. AIM OF THE REVIEW: A organized summary of the botany, traditional uses, phytochemistry, pharmacology, toxicology, available marketed formulations and filed patents were presented to explore the future therapeutic potential and scientific potential of this herb. MATE
PubMed: 34181958Role of Cissus quadrangularis in the Management of Osteoporosis: An Overview.
This article aims to provide a comprehensive review of Cissus quadrangularis (CQ), which is a traditional medicinal herb and has a potential osteoprotective effect. CQ is a perennial climber of family Vitaceae that is commonly found in the hotter parts of India. It is most widely used in India for improving bone health and is well known as "hadjod." It shows an anti-osteoporotic effect through different pathways mechanisms. It is natural matrices of excellence with proven bioactivity. Several cell line and animal studies demonstrated its protective nature against many diseases such as osteopor
PubMed: 34375512BACKGROUND: Diabetic cardiomyopathy (DCM) is an age-related disease, and its progression is accompanied by hyperglycaemia, cardiac dysfunction, and myocardial structural and functional abnormalities. MATERIAL AND METHODS: Rats were fed with an HFD for 12 weeks, followed by single-shot low-dose streptozotocin (35 mg/kg; i.p.). The treatment was performed by EECQ (200 mg/kg/day, orally) for six weeks. RESULTS: The extract EECQ improves glucose, insulin tolerance tests and hypercholesteremia. DCM is characterized by cardiac dysfunction, cardiac biomarkers CKMB and LDH, which were attenuated by th
PubMed: 35896310The effects of Cissus quadrangularis on bone-related biomarkers in humans: a systematic review and meta-analysis.
BACKGROUND: Maintaining bone health is vital, particularly for aging populations prone to bone disorders. Cissus quadrangularis (CQ), a traditional medicinal plant, is increasingly recognized for its potential benefits in promoting bone health, including the effects on bone-related biomarkers promoting bone healing and bone density improvement. This study aimed to evaluate the effects of CQ on bone-related biomarkers in humans as the primary objective and to assess its impact on other clinical outcomes as a secondary objective. METHODS: A systematic search of PubMed, Embase, Scopus, and the Co
PubMed: 40707943Cissus quadrangularis extract attenuates diabetic nephropathy by altering SIRT1/DNMT1 axis.
OBJECTIVES: Hyperglycemia-induced SIRT1, DNMT1, SODs, as well as oxidative stress, play a pivotal role in the progression of diabetic nephropathy. Cissus quadrangularis, holds antioxidant and hypoglycemic activity; however, a direct link between its activity and prevention of diabetic nephropathy has not been ascertained yet. Accordingly, we aimed to delineate the protective effect of ethanolic extract of Cissus quadrangularis (EECQ) against high-fat diet/streptozotocin (HFD/STZ) induced diabetic nephropathy rats. METHODS: The control group was fed with a normal chow diet. Rats kept on an HFD
PubMed: 34128987Seguridad y Precauciones
El uso de Cissus quadrangularis debe abordarse con precaución debido a su actividad biológica sobre sistemas endocrinos y metabólicos. En cuanto al embarazo y la lactancia, no existe evidencia científica suficiente que garantice la seguridad del consumo de esta planta en mujeres gestantes o lactantes; por lo tanto, su uso está contraindicado en estos grupos. Debido a que los efectos sobre el desarrollo fetal y la transferencia a través de la leche materna no han sido estudiados en humanos, se debe evitar cualquier ingesta para prevenir riesgos potenciales no identificados. Para niños menores de 12 años, el uso no está recomendado. La fisiología pediátrica es altamente sensible a cambios en los niveles hormonales y metabólicos, y al no existir estudios de seguridad que establezcan dosis pediátricas seguras, el riesgo de interferencia con el crecimiento o el desarrollo endocrino es una preocupación clínica válida. Respecto a las interacciones farmacológicas, se deben considerar los siguientes mecanismos: (1) Hipoglucemiantes (como la metformina o insulina): Dado que los extractos de Cissus pueden reducir los niveles de glucosa en sangre (hipoglucemia), su uso concomitante podría potenciar excesivamente el efecto de estos fármacos, aumentando el riesgo de crisis hipoglucémicas.
Perfil completo: Ver todos los usos y evidencia de Cissus →